PET/MR bests PET/CT in identifying prostate cancer recurrence

06/21/2013 | Medscape (free registration)

PET/MR imaging with 11C-choline for restaging of prostate cancer was well-tolerated and able to identify more small local recurrences than PET/CT, according to a study presented at the SNMMI Annual Meeting. The radiation dose exposure with PET/MR imaging is about 80% lower than with PET/CT, researchers said, suggesting the approach may be particularly beneficial for patients who need a number of tests.

View Full Article in:

Medscape (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
European Sales Manager
SentreHEART, Inc.
Germany, Benelux, UK
REG AFFAIRS PROJ MGR - 1400000A7F
Abbott
San Jose, CA
SPECIALIST II SYSTEMS INTEGRATION - 140000033P
Abbott
Dallas, TX
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD